Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397181 | 1.00 | NPC1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3435915 | 1.00 | NPC1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3397185 | 1.00 | NPC1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3427572 | 0.97 | GRIN1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL4339151 | 0.97 | GRIN1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3427709 | 0.92 | NPC1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3406007 | 0.92 | NPC1 (0.45) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3402815 | 0.88 | AMY1A (0.44) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL4350999 | 0.88 | AMY1A (0.44) | NPC1RAB9AGRIN1GRIN2BSENP1 | |
| SCHEMBL3426908 | 0.88 | GRIN1 (0.32) | NPC1RAB9AGRIN1GRIN2BSENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277636-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITé LAVAL (CA) | 2024-08-22 | — | — | US | claimed |
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INST NAT SANTE RECH MED (FR) | 2024-06-20 | — | — | US | claimed |
| EP-4358947-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITE DE BORDEAUX (FR) | 2024-05-01 | — | — | EP | claimed |
| CN-117897147-A | Combination comprising at least one serotonin reuptake inhibitor and at least one potassium chloride type 2 cotransporter stimulator and medical use thereof | 波尔多大学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023125404-A1 | SPINAL CORD INJURY TARGETED DRUG, POLYMER-HYDROPHOBIC COMPOUND MICELLE, AND PREPARATION METHOD FOR SPINAL CORD INJURY TARGETED DRUG | 浙江大学 | 2023-07-06 | — | — | WO | claimed |
| CN-113813262-B | Application of CLP257 in preparation of anxiety prevention and treatment medicines | 徐州医科大学 | 2023-04-11 | — | — | CN | claimed |
| WO-2022268738-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | Universite de Bordeaux (FR) | 2022-12-29 | — | — | WO | claimed |
| EP-4108238-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITE DE BORDEAUX (FR) | 2022-12-28 | — | — | EP | claimed |
| WO-2022219021-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-10-20 | — | — | WO | claimed |
| CN-114452256-A | Spinal cord injury targeted drug, polymer-hydrophobic compound micelle and preparation method thereof | 浙江大学 | 2022-05-10 | — | — | CN | claimed |
| EP-4719435-A2 | COMPOSITIONS TO TREAT OBESITY BY TARGETING KCC2 AND NKCC1 | The Jackson Laboratory (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4689110-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-3873439-B1 | SPAK KINASE INHIBITORS AS NEUROPROTECTIVE AGENTS | US GOV VETERANS AFFAIRS (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024243538-A2 | METHODS AND COMPOSITIONS TO TREAT OBESITY BY TARGETING KCC2 AND NKCC1 | THE JACKSON LABORATORY (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024206175-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROQR THERAPEUTICS II B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| US-20220281930-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | DUKE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| US-11414379-B2 | SPAK kinase inhibitors as neuroprotective agents | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-08-16 | — | — | US | disclosed |
| EP-4017873-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | Duke University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114452256-A | Spinal cord injury targeted drug, polymer-hydrophobic compound micelle and preparation method thereof | 浙江大学 | 2022-05-10 | — | — | CN | disclosed |
| US-11246879-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulai Therapeutics, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414379-B2 | SPAK kinase inhibitors as neuroprotective agents | SBK1, DAPK2, SPAST | NPC1 1400/4885RAB9A 3959/4885GRIN1 337/4885 |
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | SLC6A13, SLC6A1, CLCN2 | NPC1 334/4885RAB9A 3241/4885GRIN1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.